Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now. Qi X, Shi Q, Xuhong J, Zhang Y, et al. Breast Cancer Res 2023;25:113.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Qi X, Shi Q, Xuhong J, Zhang Y, et al. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now. Breast Cancer Res 2023;25:113.
PMID: 37789330